Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial

Documenti analoghi

• Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m 2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist
  di: Carel W. le Roux, et al.
  Pubblicazione: (2025)
• Why do patients with obesity discontinue glucagon‐like peptide 1 analogues?
  di: Faisal I. Almohaileb, et al.
  Pubblicazione: (2025)
• Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
  di: W. Timothy Garvey, et al.
  Pubblicazione: (2024)
• Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)
  di: Sean Wharton, et al.
  Pubblicazione: (2024)
• Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
  di: David C. Klonoff, et al.
  Pubblicazione: (2024)